Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants
Go back to Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.15 +0.06 (5.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.09 | 52 Week High | $11.69 | |||
| Open | $1.07 | 52 Week Low | $4.50 | |||
| Day High | $1.15 | P/E | N/A | |||
| Day Low | $1.04 | EPS | $-0.28 | |||
| Volume | 6,484,820 | |||||
